Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$176000.0.

  • TriSalus Life Sciences' Cash from Investing Activities fell 414.2% to -$176000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$847000.0, marking a year-over-year decrease of 2698.65%. This contributed to the annual value of -$345000.0 for FY2024, which is 7827.46% up from last year.
  • As of Q3 2025, TriSalus Life Sciences' Cash from Investing Activities stood at -$176000.0, which was down 414.2% from $93000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year Cash from Investing Activities high stood at $93000.0 for Q2 2025, and its period low was -$1.6 million during Q3 2022.
  • Over the past 4 years, TriSalus Life Sciences' median Cash from Investing Activities value was -$74000.0 (recorded in 2023), while the average stood at -$301066.7.
  • Data for TriSalus Life Sciences' Cash from Investing Activities shows a peak YoY increase of 25500.0% (in 2025) and a maximum YoY decrease of 98181.82% (in 2025) over the last 5 years.
  • TriSalus Life Sciences' Cash from Investing Activities (Quarter) stood at -$272000.0 in 2022, then crashed by 36.76% to -$372000.0 in 2023, then skyrocketed by 86.56% to -$50000.0 in 2024, then plummeted by 252.0% to -$176000.0 in 2025.
  • Its last three reported values are -$176000.0 in Q3 2025, $93000.0 for Q2 2025, and -$714000.0 during Q1 2025.